World Library  
Flag as Inappropriate
Email this Article


Tribolium castaneum telomerase catalytic subunit, TERT, bound to putative RNA template and telomeric DNA (PDB 3KYL)
RNA-directed DNA polymerase
A conceptual diagram showing the protein component of telomerase (TERT) in grey and the RNA component (TR) in yellow
EC number
CAS number 9068-38-6
IntEnz IntEnz view
ExPASy NiceZyme view
MetaCyc metabolic pathway
PRIAM profile
PDB structures RCSB PDB PDBe PDBsum
Gene Ontology AmiGO / EGO

Telomerase also called telomere terminal transferase[1] is a ribonucleoprotein that adds the polynucleotide "TTAGGG" to the 3' end of telomeres, which are found at the ends of eukaryotic chromosomes. A telomere is a region of repetitive sequences at each end of a chromatid, which protects the end of the chromosome from deterioration or from fusion with neighbouring chromosomes.

Telomerase is a reverse transcriptase enzyme that carries its own RNA molecule (with the pattern of "CCCAAUCCC" in vertebrates), which is used as a template when it elongates telomeres.


  • History 1
  • Human telomerase structure 2
  • Function 3
  • Clinical implications 4
    • Aging 4.1
      • Premature aging 4.1.1
    • Cancer 4.2
      • Drugs 4.2.1
        • Immunotherapy
        • Targeted apoptosis
    • Heart disease, diabetes and quality of life 4.3
    • Rare human diseases 4.4
  • See also 5
  • References 6
  • Further reading 7
  • External links 8


The existence of a compensatory mechanism for telomere shortening was first predicted by Soviet biologist Alexey Olovnikov in 1973,[2] who also suggested the telomere hypothesis of aging and the telomere's connections to cancer.

Telomerase was discovered by Carol W. Greider and Elizabeth Blackburn in 1984 in the ciliate Tetrahymena.[3] Together with Jack W. Szostak, Greider and Blackburn were awarded the 2009 Nobel Prize in Physiology or Medicine for their discovery.[4]

The role of telomeres and telomerase in cell aging and cancer was established by scientists at biotechnology company Geron with the cloning of the RNA and catalytic components of human telomerase[5] and the development of a polymerase chain reaction (PCR) based assay for telomerase activity called the TRAP assay, which surveys telomerase activity in multiple types of cancer.[6]

Its protein composition was identified in 2007 by Scott Cohen and his team at Children's Medical Research Institute (Australia).[7] The high-resolution protein structure of the Tribolium castaneum catalytic subunit of telomerase TERT was decoded in 2008 by Emmanuel Skordalakes and his team.[8]

Human telomerase structure

The human telomerase enzyme complex consists of two molecules each of human telomerase reverse transcriptase (TERT), telomerase RNA (TR or TERC), and dyskerin (DKC1).[7] The genes of telomerase subunits, which include TERT,[9] TERC,[10] DKC1[11] and TEP1,[12] are located on different chromosomes. The human TERT gene (hTERT) is translated into a protein of 1132 amino acids.[13] TERT polypeptide folds with (and carries) TERC, a non-coding RNA (451 nucleotides long). TERT has a 'mitten' structure that allows it to wrap around the chromosome to add single-stranded telomere repeats.

TERT is a reverse transcriptase, which is a class of enzyme that creates single-stranded DNA using single-stranded RNA as a template.

An image illustrating how telomerase elongates telomere ends progressively.

The protein consists of four conserved domains (RNA-Binding Domain (TRBD), retroviral reverse transcriptases, viral RNA polymerases and bacteriophage B-family DNA polymerases.

TERT proteins from many eukaryotes have been sequenced.[14]


By using TERC, TERT can add a six-nucleotide repeating sequence, 5'-TTAGGG (in vertebrates, the sequence differs in other organisms) to the 3' strand of chromosomes. These TTAGGG repeats (with their various protein binding partners) are called telomeres. The template region of TERC is 3'-CAAUCCCAAUC-5'.[15]

Telomerase can bind the first few nucleotides of the template to the last telomere sequence on the chromosome, add a new telomere repeat (5'-GGTTAG-3') sequence, let go, realign the new 3'-end of telomere to the template, and repeat the process. Telomerase reverses telomere shortening.

Clinical implications


Telomerase replaces short bits of DNA known as telomeres, which are otherwise shortened when a cell divides via mitosis.

In normal circumstances, absent telomerase, if a cell divides recursively, at some point the progeny reach their Hayflick limit,[16] which is believed to be between 50–70 cell divisions. At the limit the cells become senescent and cell division stops.[17] Telomerase allows each offspring to replace the lost bit of DNA allowing the cell line to divide without ever reaching the limit. This same unbounded growth is a feature of cancerous growth.[18]

Embryonic stem cells express telomerase, which allows them to divide repeatedly and form the individual. In adults, telomerase is highly expressed only in cells that need to divide regularly especially in male germ cells but also in activated lymphocytes and certain adult stem cells, whereas other somatic cells do not express it.[19]

A comparative biology study of mammalian telomeres indicated that telomere length of some mammalian species correlates inversely, rather than directly, with lifespan, and concluded that the contribution of telomere length to lifespan is unresolved.[20] Telomere shortening does not occur with age in some postmitotic tissues, such as in the rat brain.[21] In humans, skeletal muscle telomere lengths remain stable from ages 23 –74.[22] In baboon skeletal muscle, which consists of fully differentiated post-mitotic cells, less than 3% of myonuclei contain damaged telomeres and this percentage does not increase with age.[23] Thus, telomere shortening does not appear to be a major factor in the aging of the differentiated cells of brain or skeletal muscle. In human liver, cholangiocytes and hepatocytes show no age-related telomere shortening.[24] Another study found little evidence that, in humans, telomere length is a significant biomarker of normal aging with respect to important cognitive and physical abilities.[25]

Some experiments have raised questions on whether telomerase can be used as an anti-aging therapy, namely, the fact that mice with elevated levels of telomerase have higher cancer incidence and hence do not live longer. Telomerase also favors tumorogenesis, which leads to questions about its potential as an anti-aging therapy.[26] On the other hand, one study showed that activating telomerase in cancer-resistant mice by overexpressing its catalytic subunit extended lifespan.[27]

Exposure of T lymphocytes from HIV-infected human donors to a small molecule telomerase activator (TAT2) retards telomere shortening, increases proliferative potential and enhances cytokine/chemokine production and antiviral activity.[28]

A study that focused on Ashkenazi Jews found that long-lived subjects inherited a hyperactive version of telomerase.[29]

Mice engineered to block the gene that produces telomerase, unless they are given a certain drug, aged at a much faster rate, and died at about six months, instead of reaching the average mouse lifespan, about three years. Administering the drug at 6 months turned on telomerase production and caused their organs to be "rejuvenated," restored fertility, and normalized their ability to detect or process odors.[30][31]

A 2012 study reported that introducing the TERT gene into healthy one-year-old mice using an engineered adeno-associated virus led to a 24% increase in lifespan, without any increase in cancer.[32]

Premature aging

Premature aging syndromes including Werner syndrome, Ataxia telangiectasia, Ataxia-telangiectasia like disorder, Bloom syndrome, Fanconi anemia and Nijmegen breakage syndrome are associated with short telomeres.[33] However, the genes that have mutated in these diseases all have roles in the repair of DNA damage and the increased DNA damage may, itself, be a factor in the premature aging (see DNA damage theory of aging). An additional role in maintaining telomere length is an active area of investigation.


In vitro, when cells approach the Hayflick limit, the time to senescence can be extended by inactivating the tumor suppressor proteins - p53 and Retinoblastoma protein (pRb). Cells that have been so-altered eventually undergo an event termed a "crisis" when the majority of the cells in the culture die. Sometimes, a cell does not stop dividing once it reaches crisis. In a typical situation, the telomeres are shortened[34] and chromosomal integrity declines with every subsequent cell division. Exposed chromosome ends are interpreted as double-stranded breaks (DSB) in DNA; such damage is usually repaired by reattaching (religating) the broken ends together. When the cell does this due to telomere-shortening, the ends of different chromosomes can be attached to each other. This solves the problem of lacking telomeres, but during cell division anaphase, the fused chromosomes are randomly ripped apart, causing many mutations and chromosomal abnormalities. As this process continues, the cell's genome becomes unstable. Eventually, either fatal damage is done to the cell's chromosomes (killing it via apoptosis), or an additional mutation that activates telomerase occurs.

With telomerase activation some types of cells and their offspring become immortal (bypass the Hayflick limit), thus avoiding cell death as long as the conditions for their duplication are met. Many cancer cells are considered 'immortal' because telomerase activity allows them to divide indefinitely, which is why they can form tumors. A good example of immortal cancer cells is HeLa cells, which have been used in laboratories as a model cell line since 1951.

While this method of modeling human cancer in cell culture is effective and has been used for many years by scientists, it is also very imprecise. The exact changes that allow for the formation of the tumorigenic clones in the above-described experiment are not clear. Scientists addressed this question by the serial introduction of multiple mutations present in a variety of human cancers. This has led to the identification of mutation combinations that form tumorigenic cells in a variety of cell types. While the combination varies by cell type, the following alterations are required in all cases: TERT activation, loss of p53 pathway function, loss of pRb pathway function, activation of the Ras or myc proto-oncogenes, and aberration of the PP2A protein phosphatase. That is to say, the cell has an activated telomerase, eliminating the process of death by chromosome instability or loss, absence of apoptosis-induction pathways, and continued mitosis activation.

This model of cancer in cell culture accurately describes the role of telomerase in actual human tumors. Telomerase activation has been observed in ~90% of all human tumors,[35] suggesting that the immortality conferred by telomerase plays a key role in cancer development. Of the tumors without TERT activation,[36] most employ a separate pathway to maintain telomere length termed Alternative Lengthening of Telomeres (ALT ).[37] The exact mechanism behind telomere maintenance in the ALT pathway is unclear, but likely involves multiple recombination events at the telomere.

Two telomerase vaccines have been developed: GRNVAC1 and GV1001. GRNVAC1 isolates dendritic cells and the RNA that codes for the telomerase protein and puts them back into the patient to make cytotoxic T cells that kill the telomerase-active cells. GV1001 comes from the active site of hTERT and is recognized by the immune system that reacts by killing the telomerase-active cells.[38]

Elizabeth Blackburn et al., identified the upregulation of 70 genes known or suspected in cancer growth and spread through the body, and the activation of glycolysis, which enables cancer cells to rapidly use sugar to facilitate their programmed growth rate (roughly the growth rate of a fetus).[39]

Approaches to controlling telomerase and telomeres for cancer therapy include gene therapy, immunotherapy, small-molecule and signal pathway inhibitors.[38]


The ability to maintain functional telomeres may be one mechanism that allows cancer cells to grow in vitro for decades.[40] Telomerase activity is necessary to preserve many cancer types and is inactive in somatic cells, creating the possibility that telomerase inhibition could selectively repress cancer cell growth with minimal side effects.[41] If a drug can inhibit telomerase in cancer cells, the telomeres of successive generations will progressively shorten, limiting tumor growth.[42]

Telomerase is a good biomarker for cancer detection because most human cancers cells express high levels of it. Telomerase activity can be identified by its catalytic protein domain (hTERT). This is the rate-limiting step in telomerase activity. It is associated with many cancer types. Various cancer cells and fibroblasts transformed with hTERT cDNA have high telomerase activity, while somatic cells do not. Cells testing positive for hTERT have positive nuclear signals. Epithelial stem cell tissue and its early daughter cells are the only noncancerous cells in which hTERT can be detected. Since hTERT expression is dependent only on the number of tumor cells within a sample, the amount of hTERT indicates the severity of a cancer.[43]

The expression of hTERT can also be used to distinguish benign tumors from malignant tumors. Malignant tumors have higher hTERT expression than benign tumors. Real-time reverse transcription polymerase chain reaction (RT-PCR) quantifying hTERT expression in various tumor samples verified this varying expression.[44]

Figure 4:A) Tumor cells expressing hTERT will actively degrade some of the protein and process for presenting. The major histocompatibility complex 1(MHC1), can then present the hTERT epitote. CD8- T cells that have antibodies against hTERT will then bind to the presented epitote. B) As a result of the antigenic binding, the T cells will release cytotoxins, which can be absorbed by the affected cell. C) These cytotoxins induce multiple proteases and results in apoptosis (or cell death).

The lack of telomerase does not affect cell growth, until the telomeres are short enough to cause cells to “die or undergo growth arrest”. However, inhibiting telomerase alone is not enough to destroy large tumors. It must be combined with surgery, radiation, chemotherapy or immunotherapy.[43]

Cells may reduce their telomere length by only 50-252 base pairs per cell division, which can lead to a long lag phase.[45][46]


Immunotherapy successfully treats some kinds of cancer, such as melanoma. This treatment involves manipulating a human’s immune system to destroy cancerous cells. Humans have two major antigen identifying molecules: cytotoxic T-lymphocytes (CTL) and CD4+ helper T-lymphocytes that can destroy cells. Antigen receptors on CTL can bind to a 9-10 amino acid chain that is presented by the major histocompatibility complex (MHC) as in Figure 4. HTERT is a potential target antigen. Immunotargeting should result in relatively few side effects since hTERT expression is associated only with telomerase and is not essential in almost all somatic cells.[47] GV1001 uses this pathway.[38] Experimental drug and vaccine therapies targeting active telomerase have been tested in mouse models, and clinical trials have begun.

In 2014 Geron Corporation received permission to resume a trial of its drug imetelstat for myelofibrosis after addressing FDA concerns over liver toxicity.[48][49] Geron licensee Merck had approval of an IND for one vaccine type. Imetelstat (GRN163L) binds directly to the telomerase's RNA template. One 2015 study reported that Imetelstat caused partial or complete remission in seven of 33 patients, while a second reported that it decreased blood platelet levels in all 18 study patients with essential thrombocythemia, a disorder in which the body overproduces blood platelets, increasing the risk of blood clots.[50]

Most of the harmful cancer-related effects of telomerase are dependent on an intact RNA template. Cancer stem cells that use an alternative method of telomere maintenance are still killed when telomerase's RNA template is blocked or damaged.

Targeted apoptosis
Figure 5: A) Human telomerase RNA (hTR) is present in the cell and can be targeted. B) 2-5 anti-hTR oligonucleotides is a specialized antisense oligo that can bind to the telomerase RNA. C) Once bound, the 2-5 anti-hTR oligonucleotide recruits RNase L to the sequence. Once recruited, the RNase L creates a single cleavage in the RNA (D) and causes dissociation of the RNA sequence.

Another independent approach is to use oligoadenylated anti-telomerase antisense oligonucleotides and ribozymes to target telomerase RNA, inducing dissociation and apoptosis (Figure 5). The fast induction of apoptosis through antisense binding may be a good alternative to the slower telomere shortening.[45]

Heart disease, diabetes and quality of life

Blackburn also discovered that mothers caring for very sick children have shorter telomeres when they report that their emotional stress is at a maximum and that telomerase was active at the site of blockages in coronary artery tissue, possibly accelerating heart attacks.

In 2009, it was shown that the amount of telomerase activity significantly increased following psychological stress. Across the sample of patients telomerase activity in increased peripheral blood mononuclear cellsby 18% one hour after the end of the stress.[51]

E. V. Gostjeva et al. found no differences between colon cancer stem cells and fetal colon stem cells.[52]

A study in 2010 found that there was "significantly greater" telomerase activity in participants than controls after a three-month meditation retreat.[53]

Telomerase deficiency has been linked to diabetes mellitus and impaired insulin secretion in mice, due to loss of pancreatic insulin-producing cells.[54]

Rare human diseases

Mutations in TERT have been implicated in predisposing patients to aplastic anemia, a disorder in which the bone marrow fails to produce blood cells, in 2005.[55]

Cri du chat syndrome (CdCS) is a complex disorder involving the loss of the distal portion of the short arm of chromosome 5. TERT is located in the deleted region, and loss of one copy of TERT has been suggested as a cause or contributing factor of this disease.[56]

Dyskeratosis congenita (DC) is a disease of the bone marrow that can be caused by some mutations in the telomerase subunits.[57] In the DC cases, about 35% cases are X-linked-recessive on the DKC1 locus[58] and 5% cases are autosomal dominant on the TERT[59] and TERC[60] loci.

Patients with DC have severe bone marrow failure manifesting as abnormal skin pigmentation, leucoplakia (a white thickening of the oral mucosa) and nail dystrophy, as well as a variety of other symptoms. Individuals with either TERC or DKC1 mutations have shorter telomeres and defective telomerase activity in vitro versus other individuals of the same age.[61]

In one family autosomal dominant DC was linked to a heterozygous TERT mutation.[62] These patients also exhibited an increased rate of telomere-shortening, and genetic anticipation (i.e., the DC phenotype worsened with each generation).

See also


  1. ^ What are telomeres and telomerase?
  2. ^ Olovnikov AM (September 1973). "A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon". J. Theor. Biol. 41 (1): 181–90.  
  3. ^ Greider CW, Blackburn EH (December 1985). "Identification of a specific telomere terminal transferase activity in Tetrahymena extracts". Cell 43 (2 Pt 1): 405–13.  
  4. ^ "The Nobel Prize in Physiology or Medicine 2009". The Nobel Foundation. 2009-10-05. Retrieved 2010-10-23. 
  5. ^ Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J (September 1995). "The RNA component of human telomerase". Science 269 (5228): 1236–41.  
  6. ^ Kim, N.; Piatyszek, M.; Prowse, K.; Harley, C.; West, M.; Ho, P.; Coviello, G.; Wright, W.; Weinrich, S. (1994). "Specific association of human telomerase activity with immortal cells and cancer". Science 266 (5193): 2011–5.  
  7. ^ a b Cohen S, Graham M, Lovrecz G, Bache N, Robinson P, Reddel R (2007). "Protein composition of catalytically active human telomerase from immortal cells".  
  8. ^ Gillis AJ, Schuller AP, Skordalakes E (October 2008). "Structure of the Tribolium castaneum telomerase catalytic subunit TERT". Nature 455 (7213): 633–7.  
  9. ^ "HGNC database of human gene names - HUGO Gene Nomenclature Committee". 
  10. ^ HGNC - TERC
  11. ^ HGNC - DKC1
  12. ^ HGNC - TEP1
  13. ^ NCBI - telomerase reverse transcriptase isoform 1
  14. ^ NCBI - telomerase reverse transcriptase
  15. ^ Gavory G, Farrow M, Balasubramanian S (October 2002). "Minimum length requirement of the alignment domain of human telomerase RNA to sustain catalytic activity in vitro". Nucleic Acids Res. 30 (20): 4470–80.  
  16. ^ Hayflick L, Moorhead PS (1961). "The serial cultivation of human diploid cell strains". Exp Cell Res 25 (3): 585–621.  
  17. ^ Siegel, L (2013). Are Telomeres the Key to Aging and Cancer? The University of Utah. Retrieved 30 September 2013
  18. ^ Hanahan D & Weinberg RA (March 2011). "Hallmarks of cancer: the next generation". Cell 144 (5): 646–74.  
  19. ^ Cong YS (2002). "Human Telomerase and It's Regulation". Microbiology and Molecular Biology Reviews 66 (3): 407–425.  
  20. ^ Gomes, NM; Ryder, OA; Houck, ML; Charter, SJ; Walker, W,; Forsyth, NR; Austad, SN; Venditti, C; Pagel, M; Shay, JW; Wright, WE (2011). "Comparative biology of mammalian telomeres: hypotheses on ancestral states and the roles of telomeres in longevity determination.". Aging Cell 105 (5): 761–768.  
  21. ^ Cherif H, Tarry JL, Ozanne SE, Hales CN (2003). "Ageing and telomeres: a study into organ- and gender-specific telomere shortening". Nucleic Acids Res 31 (5): 1576–1583.  
  22. ^ "Regenerative potential of human skeletal muscle during aging.". Aging Cell 1 (2): 132–9. Dec 2002.  
  23. ^ Jeyapalan JC, Ferreira M, Sedivy JM, Herbig U (2007). "Accumulation of senescent cells in mitotic tissue of aging primates". Mech Ageing Dev 128 (1): 36–44.  
  24. ^ Verma S, Tachtatzis P, Penrhyn-Lowe S, Scarpini C, Jurk D, Von Zglinicki T, Coleman N, Alexander GJ (2012). "Sustained telomere length in hepatocytes and cholangiocytes with increasing age in normal liver". Hepatology 56 (4): 1510–1520.  
  25. ^ "Telomere length and aging biomarkers in 70-year-olds: the Lothian Birth Cohort 1936.". Neurobiol Aging 33 (7): 1486.e3–8. Jul 2012.  
  26. ^ de Magalhães JP, Toussaint O (2004). "Telomeres and telomerase: a modern fountain of youth?". Rejuvenation Res 7 (2): 126–33.  
  27. ^ Tomás-Loba A, Flores I, Fernández-Marcos PJ, Cayuela ML, Maraver A, Tejera A, Borrás C, Matheu A, Klatt P, Flores JM, Viña J, Serrano M, Blasco MA (November 2008). "Telomerase reverse transcriptase delays aging in cancer-resistant mice". Cell 135 (4): 609–22.  
  28. ^ Fauce SR, Jamieson BD, Chin AC, Mitsuyasu RT, Parish ST, Ng HL, Kitchen CM, Yang OO, Harley CB, Effros RB (November 2008). "Telomerase-Based Pharmacologic Enhancement of Antiviral Function> of Human CD8+ T Lymphocytes". J. Immunol. 181 (10): 7400–6.  
  29. ^ Atzmon G, Cho M, Cawthon RM, Budagov T, Katz M, Yang X, Siegel G, Bergman A, Huffman DM, Schechter CB, Wright WE, Shay JW, Barzilai N, Govindaraju DR, Suh Y (January 2010). "Genetic variation in human telomerase is associated with telomere length in Ashkenazi centenarians". Proc. Natl. Acad. Sci. U.S.A. 107 Suppl 1 (suppl_1): 1710–7.  
  30. ^ Jaskelioff, M; Muller, FL; Paik, JH; Thomas, E; Jiang, S; Adams, AC; Sahin, E; Kost-Alimova, M; Protopopov, A; Cadiñanos, J; Horner, JW; Maratos-Flier, E; Depinho, RA (November 2010). "Telomerase reactivation reverses tissue degeneration in aged telomerase deficient mice". Nature 469 (7328): 102–6.  
  31. ^ "Stop, rewind: the scientists slowing the ageing process". BBC News. 2011-01-26. 
  32. ^ Bernardes de Jesus, B; Vera, E; Schneeberger, K; Tejera, AM; Ayuso, E; Bosch, F; Blasco, MA (August 2012). "Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer". EMBO Molecular Medicine 4 (8): 691–704.  
  33. ^ Blasco, MA (August 2005). "Telomeres and human disease: ageing, cancer and beyond". Nature Reviews Genetics 6 (8): 611–22.  
  34. ^ Skloot, Rebecca (2010). The Immortal Life of Henrietta Lacks. New York: Broadway Paperbacks. pp. 216, 217.  
  35. ^ Shay, JW; Bacchetti, S (April 1997). "A survey of telomerase activity in human cancer". Eur. J. Cancer 33 (5): 787–91.  
  36. ^ Bryan, TM; Englezou, A; Gupta, J; Bacchetti, S; Reddel, RR (September 1995). "Telomere elongation in immortal human cells without detectable telomerase activity". EMBO J. 14 (17): 4240–8.  
  37. ^ Henson, JD; Neumann, AA; Yeager, TR; Reddel, RR (January 2002). "Alternative lengthening of telomeres in mammalian cells". Oncogene 21 (4): 598–610.  
  38. ^ a b c Tian, X; Chen, B; Liu, X (March 2013). "Telomere and Telomerase as Targets for Cancer Therapy". Applied Biochemistry and Biotechnology 160 (5): 906–21.  
  39. ^ Blackburn, EH (February 2005). "Telomeres and telomerase: their mechanisms of action and the effects of altering their functions". FEBS Lett. 579 (4): 859–62.  
  40. ^ Griffiths, Anthony J. F.; Wesslet, Susan R.; Carroll, Sean B.; Doebley, John (2008). Introduction to Genetic Analysis. W. H. Freeman.  
  41. ^ Williams, SC (January 2013). "No end in sight for telomerase-targeted cancer drugs.". Nat Med. 19 (1): 6.  
  42. ^ Blasco, MA (2001). "Telomeres in Cancer Therapy". J Biomed Biotechnol. 1 (1): 3–4.  
  43. ^ a b Shay, Jerry W,; Ying, Zou; Hiyama, Eiso; Wright, Woodring E. (2001). "Telomerase and Cancer". Human Molecular Genetics 10 (7): 677–685.  
  44. ^ Gul, Ilhami; Dundar, Ozgur; Bodur, Serkan; Tunca, Yusuf; Tutuncu, Levent (2013). "The Status of Telomerase Enzyme Activity in Benign and Malignant Gynecologic Pathologies". Balkan Medical Journal 30: 287–292.  
  45. ^ a b Saretzki, Gabriele (2003). "Telomerase inhibition as Cancer Therapy". Cancer Letter 194 (2): 209–219.  
  46. ^ Stoyanov, V (2009). "T-loop deletion factor showing speeding aging of Homo telomere diversity and evolution". Rejuvenation Research 12 (1): 52. 
  47. ^ Patel, Kunal P.; Robert H., Vonderheide (2004). "Telomerase as a tumor-associated antigen for cancer immunotherapy". Cytotechnology 45 (1-2): 91–99.  
  48. ^ "Geron's cancer drug shakes off one FDA hold but remains on pause". FierceBiotech. Retrieved 2015-06-28. 
  49. ^ "J&J bets up to $935M that Geron's drug can shake a checkered past". FierceBiotech. Retrieved 2015-06-28. 
  50. ^ Johnson, Steven Ross (September 2, 2015). "Experimental blood disorder therapy shows promise in new studies". Modern Healthcare. Retrieved September 2015. 
  51. ^ Epel, ES; Lin, J; Dhabhar, FS; Wolkowitz, OM; Puterman, E; Karan, L; Blackburn, EH (2010). "Dynamics of telomerase activity in response to acute psychological stress". Brain Behav Immun 24 (4): 531–9.  
  52. ^ "Stem cell stages and the origins of colon cancer: a multidisciplinary perspective.". Stem Cell Rev 1 (3): 243–51. 2005.  
  53. ^ Jacobs TL, et al. "Intensive meditation training, immune cell telomerase activity, and psychological mediators.". 
  54. ^  
  55. ^ Yamaguchi, H; Calado, RT; Ly, H; Kajigaya, S; Baerlocher, GM; Chanock, SJ; Lansdorp, PM; Young, NS (April 2005). "Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia". N. Engl. J. Med. 352 (14): 1413–24.  
  56. ^ Zhang, A; Zheng, C; Hou, M; Lindvall, C; Li, KJ; Erlandsson, F; Björkholm, M; Gruber, A; Blennow, E; Xu, D (April 2003). "Deletion of the Telomerase Reverse Transcriptase Gene and Haploinsufficiency of Telomere Maintenance in Cri du Chat Syndrome". Am. J. Hum. Genet. 72 (4): 940–8.  
  57. ^ Yamaguchi, H (June 2007). "Mutations of telomerase complex genes linked to bone marrow failures". J Nippon Med Sch 74 (3): 202–9.  
  58. ^ Heiss, NS; Knight, SW; Vulliamy, TJ; Klauck, SM; Wiemann, S; Mason, PJ; Poustka, A; Dokal, I (May 1998). "X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions". Nat. Genet. 19 (1): 32–8.  
  59. ^ Vulliamy, TJ; Walne, A; Baskaradas, A; Mason, PJ; Marrone, A; Dokal, I (2005). "Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure". Blood Cells Mol. Dis. 34 (3): 257–63.  
  60. ^ Vulliamy, T; Marrone, A; Goldman, F; Dearlove, A; Bessler, M; Mason, PJ; Dokal, I (September 2001). "The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita". Nature 413 (6854): 432–5.  
  61. ^ Marrone, A; Walne, A; Dokal, I (June 2005). "Dyskeratosis congenita: telomerase, telomeres and anticipation". Current Opinion in Genetics & Development 15 (3): 249–57.  
  62. ^ Armanios, M; Chen, JL; Chang, YP; Brodsky, RA; Hawkins, A; Griffin, CA; Eshleman, JR; Cohen, AR; Chakravarti, A; Hamosh, A; Greider, CW (November 2005). "Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita". Proc. Natl. Acad. Sci. U.S.A. 102 (44): 15960–4.  

Further reading

External links

  • The Telomerase Database - A Web-based tool for telomerase research.
  • Three-dimensional model of telomerase at MUN
  • Elizabeth Blackburn's seminars: Telomeres and Telomerase
  • Telomerase at the US National Library of Medicine Medical Subject Headings (MeSH)
  • Puri, Neelu; Girard, Jennifer (September 23, 2013). "Novel Therapeutics Targeting Telomerase and Telomeres" (PDF). Journal of Cancer Science & Therapy.  
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.